Clearside Biomedical, Inc. CLSDQ
0.25
0.00
0.00%
as of 22 Jul
- Market cap
- $2.2M
- P/E
- 0.0×
Follow CLSDQ
| Sep '25 | Jun '25 | Mar '25 | Dec '24 | Older periods | |
|---|---|---|---|---|---|
| 58.59% | 71.96% | 91.00% | 125.45% |
+8 more TTM periods Free account |
|
| (127.43%) | (112.50%) | (103.03%) | (116.16%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(307.11%) | (234.80%) | (218.51%) | (174.33%) | |
Average Days of Receivables |
29.16 | 71.49 | 149.14 | 111.21 | |
Free Cash Flow per Share |
(4.15) | (4.28) | (4.60) | (5.22) | |
Free Cash Flow |
(21.75) | (22.23) | (23.61) | (25.67) | |
Capital Expenditures |
(0.45) | (0.51) | (0.93) | (0.98) | |
Piotroski F-Score |
1.00 | 1.00 | 1.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
45.16% | 55.20% | 70.25% | 131.13% | |
Accounts Receivable Turnover |
6.32 | 6.49 | 3.11 | 4.37 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.37 | 0.00 | |
Inventory Turnover |
— | — | 0.00 | — | |
Average Days of Payables |
0.00 | 0.00 | 1,158.56 | 0.00 | |
Days of Inventory on Hand |
— | — | 0.00 | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
397.24% | 346.11% | 463.28% | 1,117.19% | |
Selling, General and Administrative Expense of Revenue |
380.59% | 268.99% | 313.68% | 709.56% | |
Share Based Compensation of Revenue |
99.94% | 89.92% | 110.84% | 271.21% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.82 | 0.78 | 0.74 | 0.72 | |
Depreciation/Fixed assets |
0.09 | 0.03 | (0.02) | (0.03) | |
Capex/Depreciation |
(1.62) | (5.44) | 16.59 | 8.65 | |
Revenue per Share |
0.64 | 0.80 | 0.73 | 0.34 | |
Operating CF per Share |
(4.07) | (4.18) | (4.42) | (5.02) | |
Capex per Share |
(0.09) | (0.10) | (0.18) | (0.20) | |
Capex to Sales |
0.14 | 0.12 | 0.25 | 0.59 | |
Net Profit Margin |
(780.93%) | (665.22%) | (818.60%) | (2,064.42%) |
Columns are period end dates